Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series-Reference-Cited by-同舟云学术

Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series

Published:2018-10-17 Issue:12 Volume:9 Page:1782-1787
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Kanazu Masaki¹^ORCID,Edahiro Ryuya¹,Krebe Hiroyuki¹,Nishida Kohei¹,Ishijima Mikako¹,Uenami Takeshi¹,Akazawa Yuki¹,Yano Yukihiro¹,Yamaguchi Toshihiko¹,Mori Masahide¹

Affiliation:

1. Department of Thoracic Oncology; National Hospital Organization, Toneyama National Hospital; Osaka Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12894/fullpdf

Reference16 articles.

1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

2. PD-1 and its ligands in tolerance and immunity;Keir;Annu Rev Immunol,2008

3. PD-1 and PD-1 ligands: From discovery to clinical application;Okazaki;Int Immunol,2007

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for pulmonary infection in patients with non-small cell lung cancer: a Meta-analysis;BMC Pulmonary Medicine;2024-07-22

2. Imaging findings can’t mean everything in the era of immunotherapy: a case report and literature review;Immunotherapy;2024-02

3. Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges;Genes;2023-10-04

4. Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer;Frontiers in Immunology;2023-05-22

5. Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2;Cells;2022-12-12